# US 2013/0157263 A1 · Methods and compositions for seamless cloning of nucleic acid molecules

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157263 A1
- Document ID: US20130157263A1
- Status: Published application
- Kind: A1
- Application number: 13/666,923
- Filed: 2012-11-01
- Published: 2013-06-20
- Earliest claimed: 2003-08-08
- Assignees: Life Technologies Corporation
- Inventors: Jonathan CHESNUT; Knut Madden; Miroslav Dudas; Louis Leong; Adam Harris
- Web page: https://patentgrep.com/patent/US20130157263A1

## CPC

- C12P 19/34: Polynucleotides, e.g. nucleic acids, oligoribonucleotides
- C07H 21/04: with deoxyribosyl as saccharide radical
- C12N 9/90: Isomerases (5.)
- C12N 15/10: Processes for the isolation, preparation or purification of DNA or RNA (chemical preparation of DNA or RNA C07H21/00; preparation of non-structural polynucleotides from microorganisms or with enzymes C12P19/34)
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/64: General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
- C12N 15/66: General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
- C12N 15/86: Viral vectors
- C12N 2310/111: spanning the whole gene, or a large part of it
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2330/30: chemically synthesised
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N 2800/30: Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
- C12N 2800/70: Vectors containing special elements for cloning, e.g. topoisomerase, adaptor sites
- C12Y 599/01: Other isomerases (5.99.1)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present invention is in the fields of biotechnology and molecular biology. More particularly, the present invention relates to cloning or subcloning one or more nucleic acid molecules comprising one or more type IIs restriction enzyme recognition sites. The present invention also embodies cloning such nucleic acid molecules using recombinational cloning methods such as those employing recombination sites and recombination proteins. The present invention also relates to nucleic acid molecules (including RNA and iRNA), as well as proteins, expressed from host cells produced using the methods of the present invention.

## Claims

### Claim 1

A method of producing an RNA molecule for use as an interfering RNA comprising:
(a) identifying one or more target nucleic acid sequences;
(b) preparing one or more nucleic acid molecules which encode one or more interfering RNAs, wherein said interfering RNAs bind to said one or more target nucleic acid sequences;
(c) combining
(i) one or more first nucleic acid molecules encoding one or more interfering RNAs flanked by one or more first type IIs restriction enzyme recognition sites;
(ii) one or more second nucleic acid molecules comprising one or more selectable markers flanked by one or more second type IIs restriction enzyme recognition sites; and
(iii) one or more site-specific type IIs restriction enzymes; and
(d) incubating said combination under conditions sufficient to join one or more of said nucleic acid molecules encoding one or more interfering RNAs and one or more of said second nucleic acid molecules, thereby producing one or more desired product nucleic acid molecules;
(e) inserting said one or more product nucleic acid molecules into a host cell; and
(f) expressing said one or more interfering RNAs in said host cell.

### Claim at position 2

2-8. (canceled)

### Claim 9 (depends on 1)

The method of claim 1, wherein said first nucleic acid molecule and/or said second nucleic acid molecule further comprises one or more recombination sites.

### Claim 10 (depends on 9)

The method of claim 9, wherein said first nucleic acid molecule and/or said second nucleic acid molecule further comprises one or more topoisomerase recognition sites and/or one or more topoisomerases.

### Claim 11 (depends on 10)

The method of claim 10, wherein said first nucleic acid molecule and/or said second nucleic acid molecule comprises two or more recombination sites.

### Claim 12 (depends on 11)

The method of claim 11, wherein said topoisomerase recognition site, if present, is flanked by said two or more recombination sites.

### Claim 13 (depends on 12)

The method of claim 12, wherein said recombination sites are selected from the group consisting of attB sites, attP sites, attL sites, attR sites, lox sites, psi sites, tnpI sites, dif sites, cer sites, frt sites, and mutants, variants and derivatives thereof.

### Claim at position 8

14-20. (canceled)

### Claim 21

A vector comprising:
(a) one or more toxic genes;
(b) one or more type IIs restriction enzyme recognition sites; and
(c) one or more site-specific recombination sites.

### Claim 22 (depends on 21)

The vector of claim 21, wherein said type IIs restriction enzyme recognition sites are selected from the group consisting of BsaI, BbsI, BbvII, BsmAI, BspMI, Eco3II, BsmBI, BaeI, FokI, HgaI, SlaNI and Sth132L

### Claim 23 (depends on 21)

The vector of claim 21, wherein said recombination sites are selected from the group consisting of attB sites, attP sites, attL sites, attR sites, lox sites, psi sites, tnpl sites, dif sites, cer sites,frt sites, and mutants, variants and derivatives thereof.

### Claim 24 (depends on 21)

The vector of claim 21, wherein said vector further comprises one or more topoisomerase recognition sites and/or one or more topoisomerases.

### Claim 25 (depends on 24)

The vector of claim 24, wherein said molecule comprises two or more recombination sites.

### Claim 26 (depends on 24)

The vector of claim 24, wherein said topoisomerase recognition site, if present, is flanked by said two or more recombination sites.

### Claim 27 (depends on 24)

The vector of claim 24, wherein said topoisomerase recognition site, if present, is recognized and bound by a type I topoisomerase.

### Claim 28 (depends on 27)

The vector of claim 27, wherein said type I topoisomerase is a type IB topoisomerase.

### Claim 29

A method of regulating the expression of one or more genes in a transgenic cell or a transgenic animal using interfering RNA, comprising:
(a) identifying one or more target nucleic acid sequences in said cell or animal;
(b) preparing one or more nucleic acid molecules which encode one or more interfering RNAs, wherein said interfering RNAs bind to said one or more target nucleic acid sequences;
(c) combining
(i) one or more first nucleic acid molecules encoding one or more interfering RNAs flanked by one or more first type IIs restriction enzyme recognition sites;
(ii) one or more second nucleic acid molecules comprising one or more selectable markers flanked by one or more second type IIs restriction enzyme recognition sites; and
(iii) one or more site-specific type IIs restriction enzymes; and
(d) incubating said combination under conditions sufficient to join one or more of said one or more nucleic acid molecules encoding one or more interfering RNAs and one or more of said second nucleic acid molecules, thereby producing one or more desired product nucleic acid molecules;
(e) inserting said one or more interfering RNA-containing product nucleic acid molecules into said cell or one or more cells of said animal, under conditions such that said one or more interfering RNAs bind to said one or more target nucleic acid sequences, thereby regulating expression of said one or more genes.

### Claim 30 (depends on 29)

The method of claim 29, wherein said expressed interfering RNA is between 35-60 nucleotides in length.

### Claim 31 (depends on 30)

The method of claim 30, wherein said expressed interfering RNA forms a hairpin loop.

### Claim 32 (depends on 31)

The method of claim 31, wherein said hairpin loop is between 4-8 nucleotides in length.

### Claim 33 (depends on 32)

The method of claim 32, wherein said hairpin loop comprises regions of complementarity that are between 18-25 nucleotides in length.

### Claim 34 (depends on 29)

The method of claim 29, wherein said regulation results in decreased expression of said one or more genes.
